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Summary Despite the growing field of interest in the role of pulmonary oxidative
stress in chronic obstructive pulmonary disease (COPD), barely any data are
available with respect to antioxidant capacity in the peripheral musculature of these
patients. The main objective of this study was to assess in detail the antioxidant
status in skeletal muscle of patients with COPD. Biopsies from the vastus lateralis of
21 patients with COPD and 12 healthy age-matched controls were analysed. Total
antioxidant capacity, vitamin E, glutathione, and uric acid levels were determined
and the enzyme activities of superoxide dismutase, glutathione reductase,
glutathione peroxidase, and glutathione-S-transferase were measured. Malondial-
dehyde was measured as an index of lipid peroxidation. The total antioxidant
capacity and the uric acid levels were markedly higher in COPD patients than in
healthy controls (25%, P ¼ 0:006 and 24%, P ¼ 0:029; respectively). Glutathione-S-
transferase activity was also increased (35%; P ¼ 0:044) in patients compared to
healthy subjects. Vitamin E level was lower in patients than in controls (Po0.05).
The malondialdehyde level was not different between the two groups. It can be
concluded that the muscle total antioxidant capacity is increased in patients with
COPD. Together with the reduced vitamin E levels, the increased glutathione-S-
transferase activity and normal levels of lipid peroxidation products, these findings
suggest that the antioxidant system may be exposed to and subsequently triggered
by elevated levels of reactive oxygen species.
& 2004 Elsevier Ltd. All rights reserved.
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Introduction
Evidence is accumulating that oxidative stress plays
an important role in chronic obstructive pulmonary
disease (COPD). Considerable attention has espe-
cially been paid to oxidative stress in the pulmon-
ary compartment during the last decade.1 Free
radical formation is associated with local inflam-
mation and cigarette smoking and may result in the
inactivation of antiproteases, airspace epithelial
damage, mucus hypersecretion, increased influx of
neutrophils into lung tissue, and the expression of
pro-inflammatory mediators.1,2 In addition to the
pulmonary impairment, skeletal muscle wasting
and muscle dysfunction are hallmarks of COPD.3,4
Likewise, oxidative stress may also be involved in
the systemic consequences of COPD. Oxidative
stress occurs when the balance between oxidants,
for instance reactive oxygen species (ROS), and
antioxidants shifts in favour of the ROS. A few
studies indicate that the antioxidant status is
impaired at the systemic level: increased levels of
lipid peroxidation products have been demon-
strated in serum of patients with stable COPD.5 In
patients with acute exacerbations, but not in
clinical stable condition, plasma antioxidant capa-
city was reduced.5 After exercise, serum levels of
lipid peroxidation products and oxidized glu-
tathione were increased in patients compared to
controls.6–8 The latter findings indicate that ex-
ercise-induced oxidative stress occurred and it is
therefore most likely that the source of oxidative
stress is the exercising muscle. A direct indication
of oxidative stress in skeletal muscle comes from a
study performed by Allaire et al. who found
increased accumulation of lipofuscin, a marker of
oxidative damage, in vastus lateralis biopsies from
COPD patients.9 Many diseases are associated with
oxidative stress and the use of antioxidant supple-
ments became very popular the last decades.
However, the adverse side effects and toxicity of
these supplements are not always recognized.10
Moreover, a detailed study is required to estab-
lish if and at what level the muscular antioxidant
defence system is impaired in COPD in order to
create a platform from which targeted intervention
strategies can be developed.
Therefore, the aim of the present study was to
assess in detail the antioxidant status in skeletal
muscle of patients with COPD compared to healthy
controls in rest. For this purpose the total
antioxidant capacity was measured. In addition,
the activities of several key antioxidant enzymes
were measured, including superoxide dismutase
(SOD), glutathione peroxidase (GPX), glutathione
reductase (GR), and glutathione-S-transferase
(GST). Also, the contents of total glutathione, uric
acid, and vitamin E were measured. Finally,
malondialdehyde (MDA) was determined as an
index of lipid peroxidation.
Methods
A group of 21 patients with moderate to severe
airflow obstruction and 12 healthy age-matched
volunteers was studied. All patients had COPD
according to ATS guidelines11 chronic airflow
limitation, defined as measured forced expiratory
volume in 1 s (FEV1) less than 70% of reference
FEV1. Furthermore, patients had irreversible ob-
structive airway disease (less than 10% improve-
ment of FEV1 predicted baseline after b2-agonist
inhalation). They were in clinically stable condition
and not suffering from a respiratory tract infection
or an exacerbation of their disease at least 4 weeks
prior to the study. Exclusion criteria were malig-
nancy, cardiac failure, distal arteriopathy, recent
surgery, severe endocrine, hepatic or renal dis-
orders and use of anticoagulant medication. The
healthy age-matched control subjects were volun-
teers recruited through advertisement in a local
newspaper. Written informed consent was obtained
from all subjects and the study was approved by the
medical ethical committee of the University Hospi-
tal Maastricht (Maastricht, The Netherlands).
Pulmonary function tests
All patients and control subjects underwent spiro-
metry to determine FEV1. Forced vital capacity
(FVC) was assessed by whole-body plethysmography
and diffusion capacity for carbon monoxide (DLCO)
was measured by using the single-breath method
(Masterlab, Jaeger, Wurzburg, Germany). All values
obtained were related to a reference value and
expressed as percentage of the predicted value.12
Arterial oxygen tension (PaO2) was determined
(ABL 330; Radiometer, Copenhagen, Denmark)
while breathing room air.
Assessment of body composition
Body height and weight were assessed. Whole-body
fat-free mass (FFM) was determined by bioelec-
trical impedance (Xitron 4000b, Xitron technolo-
gies, San Diego, California, USA) as described
previously.13 Weight parameters were adjusted for
body surface, resulting in the body mass index (BMI)
and FFM index (FFMI).14
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Muscle strength
Isokinetic muscle strength of the dominant knee
extensor (quadriceps) was measured using a Biodex
dynamometer (Biodex Corporation, Shirley, NY,
USA).15 The highest torque value (expressed as
Nm) of three sequential voluntary maximal con-
tractions at an angular velocity of 601/s was used.
Exercise capacity
Exercise capacity was assessed by means of cycle
ergometry. Subjects performed an incremental
(10W/min for patients and 15–25W/min for con-
trols) cycle ergometry test as described pre-
viously.16 Expired gases were investigated using
breath by breath analysis through a breathing mask
(Oxycon Betas, Jaeger, W .urzburg, Germany). Peak
VO2 and peak load were measured at the moment
of cessation of the exercise.
Collection and processing of muscle tissue
Postabsorptive muscle biopsies of the lateral part
of the quadriceps femoris were obtained under
local anaesthesia by the needle biopsy technique17
and the specimens were immediately frozen in
liquid nitrogen. The frozen biopsies were weighed
and subsequently grinded with a mortar cooled in
liquid nitrogen. The frozen powder was resus-
pended in buffer (100mM sodium phosphate, pH
7.4) to a final concentration of 250mg tissue/ml
and directly re-frozen in liquid nitrogen and stored
at 801C until use. For the determination of
vitamin E, an aliquot of the total muscle biopsy
homogenate was used. For analysis of the other
parameters the homogenate was centrifuged (5min
at 14,000 g and 41C) and the muscle biopsy
supernatant was used. Total protein content in
the homogenates was assayed according to Smith
et al.18 using BSA as standard.
Measurements of antioxidants and lipid
peroxidation
GST activity was determined by the GST catalysed
reaction of chlorodinitrobenzene (Sigma Chemical
Co., St. Louis, USA) with reduced glutathione
(GSH), resulting in a yellow coloured product,
glutathione-dinitrobenzene, of which the increase
in absorbance was measured (2min at 340 nm).19
After correction for the non-enzymatic reaction,
the activity of GST in the sample was calculated
using the molar absorptivity coefficient of glu-
tathione-dinitrobenzene. The GR activity was de-
termined by measuring the decrease in absorbance
(2min at 340 nm) by the consumption of NADPH
(Sigma) in the enzymatic reduction of oxidized
glutathione (GSSG) to GSH by GR.20 The activity
was calculated using the molar absorptivity coeffi-
cient of NADPH. The selenium dependent GPX
activity, with H2O2 as substrate, was also deter-
mined by measuring the decrease in absorbance
(3min at 340 nm) due to the consumption of
NADPH.21 GPX activity was calculated using the
molar absorptivity coefficient of NADPH. Total
glutathione level was determined by measuring
the increase in absorbance (2min at 405 nm),
caused by the GSH driven reduction of 5’5’dithiobis
2-nitrobenzoic acid (ICN Biomedicals Inc., Costa
Mesa, USA), using the recycling method described
by Vandeputte et al.22 The activity of the SOD was
measured using the xanthine–xanthine oxidase
system (Sigma) for the generation of superoxide
anions and nitro blue tetrazolium (NBT) (Sigma):
NBT is reduced by superoxide anions to the blue
formazan which can be measured at 560nm. SOD
scavenges superoxide anions resulting in less reduc-
tion of NBT. The increase in absorbance was
measured (2min at 560nm).25 After adding an
internal standard, vitamin E nicotinate (Sigma),
vitamin E was extracted by hexane extraction.
Vitamin E concentration was determined with the
HPLC method as previously described by van Haaften
et al.23 using an Agilent HPLC system (Agilent, Palo
Alto, CA, USA) and a Nucleosil C18 column
(125 4mm2, particle size 5mm, Agilent). Uric acid
was determined in ultra filtrates with the HPLC
method described by Lux et al.24 using a Hypersil BDS
C18 end-capped column (125 4mm2, particle size
5mm, Agilent). The total antioxidant capacity was
measured by means of the Trolox equivalent anti-
oxidant capacity (TEAC) assay, as described by van
den Berg et al.:25 MBS samples were deproteinated
with trichloro-acetic acid. The absorbance (at
734nm) of the radical solution was 0.770.02. Then
the decrease in absorbance, caused by antioxidant
capacity in the sample, was measured and related to
that of trolox standards. The determination of MDA
was based on the formation of a coloured adduct of
MDA with 2-thiobarbituric acid, which was measured
according to the HPLC method described by Lepage
et al.26 using a Nucleosil C18 column (150 3.2mm2
particle size 5mm, Supelco Inc., Bellefonte, PA, USA).
Statistical analysis
Data were analysed with the unpaired Student’s
t-test (corrected for unequal variances if
appropriate) or the Pearson correlation test, as
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appropriate.27 Data are represented as the means
7SD. Differences in gender between the control
and the patient groups were examined using the w2-
test. A two-tailed probability value of less than
0.05 was considered statistically significant.
Results
Subject characteristics are presented in Table 1.
There were no statistically significant differences in
age and gender between the control and patient
groups. Lung function was clearly impaired in
patients with COPD. Patients had a lower body
mass index, a reduced peripheral muscle strength,
and a decreased exercise capacity compared to
control subjects.
The results of muscle biopsy analysis are shown in
Table 2. Total antioxidant capacity, as measured by
the TEAC, was significantly increased in COPD,
being 25% higher than in healthy controls. Muscle
tissue uric acid levels were also significantly higher
(24%) in patients compared to control subjects. The
antioxidant capacities of the TEAC and uric acid
can be directly compared on a one-to-one basis.
From this it can be calculated that the difference in
uric acid level (0.25 nmol/mg protein) accounts
only for 2% of the difference in TEAC (12 nmol/mg
protein). Glutathione levels were normal in pa-
tients. The activities of all four antioxidant
enzymes tended to be somewhat higher in COPD,
but only GST activity was statistically significant
higher (35%). The level of vitamin E, a lipid soluble
scavenger, was reduced in patients, being 66% of
control values. MDA, the marker of lipid peroxida-
tion, was not different between patients and
controls.
Muscle antioxidant status was not related to
disease severity as measured by the FEV1. In
addition, the increased antioxidant capacity can
not be explained by differences smoking history.
There were also no relations between antioxidant
status and muscle strength or exercise capacity.
Discussion
The most striking results of this study are that the
overall antioxidant capacity of peripheral skeletal
muscle in rest was higher in patients with COPD
compared to healthy age-matched control sub-
jects, whereas the vitamin E level was reduced.
These are very important findings, because they
indicate that the muscular antioxidant status is
chronically altered in COPD patients characterized
by peripheral muscle weakness and wasting. Prob-
ably the most important way by which the
antioxidant defence system can be triggered is
exposure to ROS.28–30 It is therefore likely that the
observed increased antioxidant capacity is a com-
pensatory adaptation to elevated ROS formation in
skeletal muscle of patients with COPD.
Oxidative stress occurs when the balance be-
tween oxidants, i.e. ROS, and antioxidants shifts in
favour of the ROS. The reactive superoxide anions
may subsequently give rise to hydrogen peroxide,
hydroxyl radicals, and other redox-reactive mole-
cules. An inadequate defence system may be
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Table 1 Subject characteristics.
Controls COPD
N (Female/Male) 12 (4/8) 21 (3/18)
Age (yr) 6577 6578
FEV1 (% pred) 113725 40723***
DLCO (% pred) 114716 64723***
FVC (% pred) 118718 86719***
PaO2 (kPa) 10.571.4 9.771.1
SaO2 (%) 9572.0 9471.9
Systemic characteristics:
BMI (kg/m2) 27.372 24.174**
FFMI (kg/m2) 19.871.8 17.372.9**
Exercise capacity as peak VO2 (ml/min) 21757889 8947343***
Exercise capacity as peak load (W) 193778 68729***
Leg muscle strength as peak torque (Nm) 154743 84747**
Smoking history (pack years) 1575 5177***
Values are mean7 SD; Significance of difference compared to controls: **Po0.01; ***Pp0.001. BMI: body mass index; FFMI: fat-
free mass index; DLCO: diffusion capacity for carbon monoxide; FEV1: forced expiratory volume in one second; FVC: forced vital
capacity; peak VO2: peak oxygen consumption.
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overwhelmed by the ROS, leading to damage of
proteins, lipids, and DNA, which in turn may result
in extensive cell and tissue damage. SOD catalyses
the dismutation of superoxide anions to hydrogen
peroxide, which in turn is converted to harmless
water and oxygen by the glutathione system. This
system includes the enzymes GPX, GST, and GR.
GPX and GST activities require reduced glutathione
(GSH) as a co-factor, GPX activity results in oxidized
glutathione (GSSG) and the accumulating GSSG can
subsequently be recycled to GSH via the enzyme
GR.31 Uric acid has been suggested as a ROS
scavenger, although its action in muscle has not
been studied systematically.31 ROS can also react
with lipids, forming lipid radicals and lipid peroxyl
radicals. The lipid peroxyl radicals can be sca-
venged by vitamin E, a lipid-soluble antioxidant
that plays an important role in the protection of
phospholipid membranes against oxidative da-
mage.31 Vitamin E can be recycled by, for example
GSH. Lipid peroxidation products can be detoxified
by GST. But if the scavenging capacity is insuffi-
cient, lipid peroxidation products may accumulate,
as reflected by increased MDA levels.
In the present study, the total antioxidant
capacity, as measured by the TEAC, was markedly
higher in COPD than in controls and, as mentioned
earlier, oxidative stress may very well be the
trigger. The only direct indication for muscular
oxidative stress in COPD has recently been provided
by Allaire et al., who reported accumulation of
intramuscular lipofuscin, a marker of oxidative
stress.9 An interesting side-note is that lipofuscine
contains iron, which may in turn catalyse further
oxidative reactions.32 The fact that vitamin E levels
were decreased in patients also supports this
notion, because this may reflect its utilization
during oxidative stress. Interestingly, reduced
vitamin E was reported for COPD recently in blood
as well.8 However, in the current study no
significantly increased lipid peroxidation products
(MDA) were found in the muscle biopsies from COPD
patients. There are two possible explanations for
this. The first option is that, in rest, there is no
muscular oxidative stress; thus there is a balance
between the increased antioxidant capacity and
the, supposedly elevated, free radical formation. In
this respect, it is also possible that the observed
increase in GST activity provides extra potential to
detoxify lipid peroxidation products, thereby pre-
venting a rise in MDA. Skeletal muscle fibres
generate ROS at a relative low rate continuously,
becauseB3% of total oxygen consumed leaks away
from the mitochondrial electron transport in the
form of superoxide anions. ROS formation is
dramatically increased during exercise.31 It is
therefore still possible that exercise induced
oxidative stress is responsible for reduced vitamin
E levels and the stimulated TEAC. Unlike lipofuscin,
MDA does not accumulate in the muscle cells over
time, but diffuses away from the muscle and can be
metabolized. Therefore, a second option is that, in
rest, oxidative stress and subsequent lipid perox-
idation do occur, but at such a low rate that MDA
may not be a sensible marker.
Although the present study was not designed to
determine the mechanism behind and the sources
of muscular oxidative stress in COPD, some possi-
bilities will be briefly discussed below. First of all,
mitochondria in the muscle cells are a major source
of ROS, especially during exercise. Normally, the
antioxidant status in the oxidative type I fibres is
higher compared to the less oxidative type II
fibres.31,33 However, despite the currently observed
increased total antioxidant capacity, a I-II fibre
type shift and a reduction of oxidative capacity
have consistently been observed in the vastus
lateralis of patients with COPD.34–37 This would
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Table 2 Muscle biopsy data.
Controls COPD
SOD (U/mg protein) 6.975.0 9.574.0
GR (U/mg protein) 12.872.5 13.373.6
GST (U/mg protein) 0.1770.07 0.2370.08*
GPX (nmol NADPH/min/mg protein) 20.776.7 23.176.4
Glutathione (nmol/mg protein) 18.574.9 19.675.2
TEAC (nmol Trolox Eq/mg protein) 4678.8 58712.7**
Uric acid (nmol/mg protein) 1.0470.21 1.2970.31*
Vitamin E (mg/mg tissue) 21.670.5 17.370.5*
MDA (nmol/mg protein) 0.6970.17 0.7770.37
Values are mean 7SD; Significance of difference compared to controls: *Po0.05; **Po0.01. GPX: glutathione peroxidase; GR:
glutathione reductase; GST: glutathione S-transferase; SOD: superoxide dismutase; TEAC: Trolox equivalent antioxidant
capacity; MDA: malondialdehyde.
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suggest that ROS formation in the remaining type I
fibres may be higher than normal, which is
supported by the recent study in which increased
lipofuscin accumulation was indeed greater in type
I fibres than in type II fibres.9 Because COPD
patients are certainly not more physically active
than healthy subjects, this suggests that relatively
more free radicals are produced in exercising
muscles of these patients. Baarends et al. recently
reported that leg muscle mechanical efficiency is
less in COPD compared to controls.38 This and the
reduced capacity of oxidative energy metabolism
mentioned earlier may lead to the incomplete
oxygen reduction and subsequent ROS formation.
A second source of ROS is inflammation. Systemic
inflammation is indeed common in COPD and has
been associated with muscle wasting in these
patients.39–41 There is also evidence that immune
cells that are activated during inflammation are a
source of ROS in the skeletal muscles.42,43 In
addition, there are indications that the muscle
cells themselves can be triggered by circulating
inflammatory mediators to produce ROS.44–47
A third alternative source of ROS is the xanthine
oxidase, which is an enzyme that catalyses the
conversion of hypoxanthine into uric acid, hypox-
anthine accumulates in situations of metabolic
stress (i.e. exercise and hypoxia) as a result from
AMP degradation.33 Heunks et al. demonstrated,
for COPD, that the oxidation of glutathione in blood
during exercise can be inhibited by treatment with
allopurinol, a xanthine oxidase inhibitor.6 In this
study we found elevated levels of uric acid in the
muscle biopsies from patients with COPD. Although
it can be considered as an antioxidant itself, the
observed increase of uric acid is probably of minor
importance compared to the increased total anti-
oxidant capacity in patients, as measured by TEAC.
However, an increased uric acid level may also
indicate increased xanthine oxidase activity, since
uric acid is a degradation product of AMP degrada-
tion. This is in line with a previous study in which
elevated IMP levels were observed in skeletal
muscle biopsies from COPD patients, since IMP is
an intermediate in AMP degradation.48
The present data indicate that the total muscular
glutathione level was normal in this COPD group.
Rabinovich et al. also demonstrated that muscle
glutathione was normal in COPD compared to
controls.49 Previously, Engelen et al. reported
reduced glutathione levels in vastus lateralis
biopsies from emphysema patients, which was
associated with reduced levels of its precursor,
glutamate.50 This suggests that glutathione home-
ostasis may differ between COPD sub-groups.
Alternatively, the discrepancy may reflect differ-
ences between the methodologies that were used:
Engelen et al. expressed glutathione levels per wet
weight of muscle tissue, whereas glutathione levels
were corrected for total protein level in the other
two studies.
The present data provide some new starting
points for future research. For example, the
elevated TEAC remains largely unexplained. Be-
cause the TEAC is measured in a deproteinated
sample, the contribution of enzymes can be ruled
out. Identification of the antioxidant(s) that is (are)
responsible for this increase may provide perspec-
tives for new therapies. The findings also suggest
that vitamin E supplementation might be beneficial
for COPD patients. Although evidence for a protec-
tive effect of vitamin E intake on respiratory
symptoms and lung function are inconsistent,51
there are some indications that vitamin E may
prevent oxidative stress induced muscle damage,
for example in immobilized rats52 or in humans
during surgical ischemia/reperfusion.53 More re-
search is thus required to establish whether
antioxidant supplementation in COPD patients is
beneficial from a ‘‘muscular’’ point of view.
In summary, to our knowledge, this is the first
detailed study in which several key antioxidants in
peripheral skeletal muscle were examined in COPD.
The collected data strongly suggest that the
production and handling of oxygen free radicals is
altered in muscles of COPD patients. It remains to
be explored whether this alteration is instrumental
in muscle weakness in COPD patients (Fig. 1).
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Figure 1 A schematic representation of antioxidants and
ROS formation. AMP: adenosine monophosphate; IMP:
inosine monophosphate; XO: xanthine oxidase; HX:
hypoxanthine; X: xanthine; SOD: superoxide dismutase;
GPX: glutathione peroxidase; GSH: reduced glutathione;
GSSG: oxidized glutathione; GR: glutathione reductase;
GST: glutathione S-transferase; L: lipid radical; LPOs:
lipid peroxidation products; MDA: malondialdehyde; vitE:
vitamin E.
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